ACET news

Adicet Bio filed an EX-99.1 document outlining its strategic business plans and financial expectations. The updates provided cover patient dosing status and potential program outcomes but include standard FDA and economic risk disclaimers.

Adicet Bio reported the completion of a key SLE study for prula-cel, with topline data expected in September 2026. The company also announced FDA clearance for its ADI-212 mCRPC program.

Adicet Bio delayed the release of Phase 1 results for prula-cel in lupus due to added patient follow-up. The progress in pivotal trial design suggests a smoother regulatory path forward, supporting the stock's medium-term outlook.